Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use
Background: We evaluated feasibility, safety, and total resource use of subcutaneous immunoglobulin (SCIG) in a pilot study of patients who underwent allogeneic hematopoietic cell transplant (HCT) over a 6-month period. Methods: A total of 20 eligible patients were treated with SCIG at 0.1 g/kg/week...
Guardado en:
Autores principales: | Ivan Pasic, Wael Alanazi, George Dranitsaris, Lani Lieberman, Auro Viswabandya, Dennis Dong Hwan Kim, Jeffrey H. Lipton, Fotios V. Michelis |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e6b8adf073bc4e35abc6c80347e3c072 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Hematopoietic stem cell transplantation: clinical use and perspectives
por: Barriga,Francisco, et al.
Publicado: (2012) -
CD4+ T cells in aged or thymectomized recipients of allogeneic stem cell transplantations
por: Takahashi,Hiroshi, et al.
Publicado: (2015) -
An insight into the utilization of allogenic blood transfusion and factors affecting blood transfusion in total knee replacement surgery in a tertiary care hospital in Eastern India
por: Sudipta Sekhar Das, et al.
Publicado: (2021) - Pilot and feasibility studies
-
CONCENTRATIONS OF IgG SUBCLASSES IN ALLOGENEIC BONE MARROW RECIPIENTS
por: A. V. Klimovich, et al.
Publicado: (2014)